Literature DB >> 26440866

Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension.

Omid Fatemi1,2,3,4, Cristobal Goa2,3,4, Charles Faselis3,5, Peter Kokkinos3,5,6, Vasilios Papademetriou2,7.   

Abstract

The current definition of drug-resistant hypertension includes patients with uncontrolled (URH) (taking ≥3 antihypertensive medications) and controlled hypertension (CRH; blood pressure [BP] ≤140/90 mm Hg) (taking ≥4 medications). The authors hypothesized that all-cause mortality is reduced when URH is controlled. Qualified patients followed at the Washington DC VA Medical Center were included. BPs were averaged for each year of follow-up. In 2006, among 2906 patients who met the criteria for drug-resistant hypertension, 628 had URH. During follow-up, 234 patients were controlled (group 1) and 394 patients remained uncontrolled (group 2). The mortality rate among patients with URH was 28% (110 of 394) and among patients with CRH was 13% (30 of 234), a 54% reduction (P<.01). Multivariate analysis identified independent predictors of mortality as uncontrolled HTN (hazard ratio, 2.5; 95% confidence interval, 1.67-3.75; P<.01), age (hazard ratio, 1.03; 95% confidence interval, 1.01-1.04; P<.01), and diabetes (hazard ratio, 1.46; 95% confidence interval, 1.04-2.05; P<.027). The authors conclude that controlling drug-resistant hypertension markedly reduces all-cause mortality.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26440866      PMCID: PMC8031702          DOI: 10.1111/jch.12672

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  33 in total

1.  Hypertension prevalence and stroke mortality across populations.

Authors:  Jan A Staessen; Tatiana Kuznetsova; Katarzyna Stolarz
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

2.  US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.

Authors:  Brent M Egan; Yumin Zhao; R Neal Axon
Journal:  JAMA       Date:  2010-05-26       Impact factor: 56.272

3.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

Review 4.  Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation.

Authors:  Thomas E Lohmeier; Radu Iliescu
Journal:  J Appl Physiol (1985)       Date:  2012-07-12

5.  Resistant hypertension: incidence, prevalence, and prognosis.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

Review 6.  Resistant hypertension, obstructive sleep apnoea and aldosterone.

Authors:  T Dudenbostel; D A Calhoun
Journal:  J Hum Hypertens       Date:  2011-06-09       Impact factor: 3.012

7.  Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system.

Authors:  Vasilios Papademetriou; Costas P Tsioufis; Ajay Sinhal; Derek P Chew; Ian T Meredith; Yuvi Malaiapan; Matthew I Worthley; Stephen G Worthley
Journal:  Hypertension       Date:  2014-06-16       Impact factor: 10.190

8.  Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Authors:  Brent M Egan; Yumin Zhao; Jiexiang Li; W Adam Brzezinski; Thomas M Todoran; Robert D Brook; David A Calhoun
Journal:  Hypertension       Date:  2013-08-05       Impact factor: 10.190

Review 9.  Renal sympathetic denervation for treating resistant hypertension.

Authors:  Alberto Polimeni; Antonio Curcio; Ciro Indolfi
Journal:  Circ J       Date:  2013-03-19       Impact factor: 2.993

10.  Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension.

Authors:  Omid Fatemi; Cristobal Goa; Charles Faselis; Peter Kokkinos; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-10-06       Impact factor: 3.738

View more
  8 in total

1.  Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.

Authors:  Parisa Danaietash; Pierre Verweij; Ji-Guang Wang; George Dresser; Ilkka Kantola; Mary Katherine Lawrence; Krzysztof Narkiewicz; Markus Schlaich; Marc Bellet
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-06-09       Impact factor: 2.885

2.  Assessing Barriers to and Level of Adherence to Hypertension Therapy among Palestinians Living in the Gaza Strip: A Chance for Policy Innovation.

Authors:  Nasser Ibrahim Abu-El-Noor; Yousef Ibrahim Aljeesh; Bettina Bottcher; Mysoon Khalil Abu-El-Noor
Journal:  Int J Hypertens       Date:  2020-09-24       Impact factor: 2.420

3.  Resistant Hypertension and Susceptible Outcomes: Exploring the Benefits of Aggressive Blood Pressure Control.

Authors:  Steven M Smith
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-10-05       Impact factor: 3.738

4.  Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.

Authors:  Andrea R Sabbatini; Natalia R Barbaro; Ana Paula de Faria; Rodrigo Modolo; Alessandra Mileni V Ritter; Claudio Pinho; Rivadavio Fernandes Batista Amorim; Vanessa Fontana; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-14       Impact factor: 3.738

5.  Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study.

Authors:  Anna Solini; Giuseppe Penno; Emanuela Orsi; Enzo Bonora; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Franco Cavalot; Olga Lamacchia; Marco G Baroni; Antonio Nicolucci; Giuseppe Pugliese
Journal:  BMC Med       Date:  2019-04-25       Impact factor: 8.775

6.  Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension.

Authors:  Omid Fatemi; Cristobal Goa; Charles Faselis; Peter Kokkinos; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-10-06       Impact factor: 3.738

Review 7.  Estrogen-related mechanisms in sex differences of hypertension and target organ damage.

Authors:  Andrea Rodrigues Sabbatini; Georgios Kararigas
Journal:  Biol Sex Differ       Date:  2020-06-01       Impact factor: 5.027

8.  Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology.

Authors:  Asife Sahinarslan; Emine Gazi; Meryem Aktoz; Cigdem Ozkan; Gülay Ulusal Okyay; Ozgul Ucar Elalmis; Erdal Belen; Reviewers Atila Bitigen; Ulver Derici; Neslihan Bascil Tutuncu; Aylin Yildirir
Journal:  Anatol J Cardiol       Date:  2020-09       Impact factor: 1.596

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.